These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27576300)

  • 1. Dipeptidyl peptidase-4 inhibitor approaches.
    Bloomgarden Z
    J Diabetes; 2017 Jan; 9(1):5-7. PubMed ID: 27576300
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular effects of the DPP-4 inhibitors.
    Jose T; Inzucchi SE
    Diab Vasc Dis Res; 2012 Apr; 9(2):109-16. PubMed ID: 22337893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
    Secrest MH; Udell JA; Filion KB
    Trends Cardiovasc Med; 2017 Apr; 27(3):194-202. PubMed ID: 28291655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases.
    Xie W; Song X; Liu Z
    Vascul Pharmacol; 2018 Oct; 109():17-26. PubMed ID: 29879463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Koska J; Sands M; Burciu C; Reaven P
    Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saxagliptin, alone or in combination. No fewer complications; more cases of heart failure?
    Prescrire Int; 2014 Sep; 23(152):207. PubMed ID: 25325118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Therapeutic Strategies for Type 2 Diabetes
    Yehya A; Sadhu AR
    Methodist Debakey Cardiovasc J; 2018; 14(4):281-288. PubMed ID: 30788014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycemia Lowering and Risk for Heart Failure: Recent Evidence from Studies of Dipeptidyl Peptidase Inhibition.
    Zhong J; Goud A; Rajagopalan S
    Circ Heart Fail; 2015 Jul; 8(4):819-25. PubMed ID: 26199308
    [No Abstract]   [Full Text] [Related]  

  • 10. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study.
    Leung M; Leung DY; Wong VW
    Diab Vasc Dis Res; 2016 May; 13(3):236-43. PubMed ID: 26993495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure.
    Ou SM; Chen HT; Kuo SC; Chen TJ; Shih CJ; Chen YT
    Heart; 2017 Mar; 103(6):414-420. PubMed ID: 27647170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dipeptidyl peptidase-4 inhibitor in patients undergoing bypass surgery.
    Ogawa S; Okawa Y; Sawada K; Goto Y; Fukaya S; Suzuki T
    Asian Cardiovasc Thorac Ann; 2016 Nov; 24(9):863-867. PubMed ID: 27784818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes without cardiovascular and renal diseases.
    Qiu M; Zhou X; Zhang M
    Diabetes Obes Metab; 2022 Mar; 24(3):575-577. PubMed ID: 34729884
    [No Abstract]   [Full Text] [Related]  

  • 16. In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality.
    Kelsey MD; Newby LK
    Ann Intern Med; 2022 Mar; 175(3):JC26. PubMed ID: 35226528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Novel antidiabetic drugs and cardiovascular complications].
    Pareek M; Mortensen MB; Løfgren B; Nielsen ML; Olsen MH; Andersen NH
    Ugeskr Laeger; 2018 Feb; 180(6):. PubMed ID: 29429477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.
    Bethel MA; McMurray JJV
    Circulation; 2018 Mar; 137(12):1218-1220. PubMed ID: 29555706
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
    Dawwas GK; Smith SM; Park H
    Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
    Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
    Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.